Ocean Biomedical, Inc. SEC filings OCEA
Ocean Biomedical, Inc. has 255 filings in SEC EDGAR's recent list, going back to Jul 19, 2021. Its latest annual report, Form 10-K, was filed on Apr 8, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on May 15, 2025, covering the quarter ended Mar 31, 2025. The most recent current report (Form 8-K) was filed on Aug 5, 2025 (listing notice, officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Filing | Aug 14, 2025 | Jun 30, 2025 |
| 25-NSE | Delisting notice | Aug 8, 2025 | — |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| NT 10-Q | Filing | May 14, 2024 | Mar 31, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| NT 10-Q | Filing | Nov 15, 2023 | Sep 30, 2023 |
| EFFECT | Filing | Jul 7, 2023 | — |
| CORRESP | Letter to the SEC | Jul 6, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2023 | — |
| EFFECT | Filing | Jun 22, 2023 | — |
| CORRESP | Letter to the SEC | Jun 21, 2023 | — |
| CORRESP | Letter to the SEC | Jun 15, 2023 | — |
| D | Filing | Jun 15, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2023 | — |
| CORRESP | Letter to the SEC | Jun 1, 2023 | — |
| NT 10-Q | Filing | May 16, 2023 | Mar 31, 2023 |
| UPLOAD | Letter from the SEC | May 5, 2023 | — |
| 25-NSE | Delisting notice | Feb 15, 2023 | — |
| 425 | Filing | Feb 13, 2023 | — |
| 425 | Filing | Feb 13, 2023 | — |
| 425 | Filing | Feb 13, 2023 | — |
| 425 | Filing | Feb 10, 2023 | — |
| 425 | Filing | Feb 9, 2023 | — |
| 425 | Filing | Feb 8, 2023 | — |
| 425 | Filing | Feb 7, 2023 | — |
| 425 | Filing | Feb 6, 2023 | — |
| 425 | Filing | Feb 1, 2023 | — |
| 425 | Filing | Jan 30, 2023 | — |
| DEFR14A | Filing | Jan 25, 2023 | — |
| 425 | Filing | Jan 24, 2023 | — |
| 425 | Filing | Jan 13, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 13, 2023 | — |
| PRER14A | Filing | Dec 30, 2022 | — |
| CORRESP | Letter to the SEC | Dec 30, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2022 | — |
| 425 | Filing | Dec 16, 2022 | — |
| PRER14A | Filing | Dec 14, 2022 | — |
| CORRESP | Letter to the SEC | Dec 13, 2022 | — |
| 425 | Filing | Dec 13, 2022 | — |
| 425 | Filing | Dec 8, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2022 | — |
| CORRESP | Letter to the SEC | Nov 22, 2022 | — |
| PRER14A | Filing | Nov 22, 2022 | — |
| PRER14A | Filing | Nov 18, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 9, 2022 | — |
| 425 | Filing | Nov 4, 2022 | — |
| 425 | Filing | Nov 1, 2022 | — |
| 425 | Filing | Nov 1, 2022 | — |
| PRER14A | Filing | Oct 26, 2022 | — |
| CORRESP | Letter to the SEC | Oct 26, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2022 | — |
| 425 | Filing | Sep 6, 2022 | — |
| 425 | Filing | Aug 31, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2022 | — |
| CORRESP | Letter to the SEC | Aug 12, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2022 | — |
| EFFECT | Filing | Sep 14, 2021 | — |
| CERT | Filing | Sep 13, 2021 | — |
| CORRESP | Letter to the SEC | Sep 10, 2021 | — |
| CORRESP | Letter to the SEC | Sep 10, 2021 | — |
| 8-A12B | Filing | Sep 10, 2021 | — |
| CORRESP | Letter to the SEC | Aug 19, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2021 | — |
Showing 63 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OCEA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1869974
- Former names
- Ocean Biomedical, Inc./DE (until Feb 15, 2023); Aesther Healthcare Acquisition Corp. (until Feb 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.